Cargando…

Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients

BACKGROUND: Dolutegravir is a powerful, well-tolerated integrase inhibitor with a high genetic barrier to resistance and may thus constitute the backbone of lightened regimens. METHODS: This was a monocentric, retrospective study. HIV-1-infected patients receiving dolutegravir as monotherapy (mDGV)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gubavu, Camelia, Prazuck, Thierry, Niang, Mohamadou, Buret, Jennifer, Mille, Catherine, Guinard, Jérôme, Avettand-Fènoël, Véronique, Hocqueloux, Laurent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4790618/ https://www.ncbi.nlm.nih.gov/pubmed/26712907 http://dx.doi.org/10.1093/jac/dkv430

Ejemplares similares

HIV-DNA in the Genital Tract of Women on Long-Term Effective Therapy Is Associated to Residual Viremia and Previous AIDS-Defining Illnesses
por: Prazuck, Thierry, et al.
Publicado: (2013)

S03-04 OA. Transitional and central memory CD4 T cells are highly infected in long term non progressors and elite controllers
por: Descours, B, et al.
Publicado: (2009)

High Prevalence of Cervical High-Risk Human Papillomavirus Harboring Atypical Genotypes in Human Immunodeficiency Virus -Infected and -Uninfected First-Generation Adult Immigrant Women Originating from Sub-Saharan Africa and Living in France
por: Mboumba Bouassa, Ralph-Sydney, et al.
Publicado: (2020)

Investigation of a family outbreak of COVID-19 using systematic rapid diagnostic tests raises new questions about transmission
por: Prazuck, Thierry, et al.
Publicado: (2020)

Evaluation of performance of two SARS-CoV-2 Rapid IgM-IgG combined antibody tests on capillary whole blood samples from the fingertip
por: Prazuck, Thierry, et al.
Publicado: (2020)

High Prevalence of Anal and Oral High-Risk Human Papillomavirus in Human Immunodeficiency Virus–Uninfected French Men Who Have Sex With Men and Use Preexposure Prophylaxis
por: Mboumba Bouassa, Ralph-Sydney, et al.
Publicado: (2019)

2486. Clinical Outcomes of Patients Treated with Dolutegravir Functional Monotherapy or Dolutegravir plus an Active Non-cytosine Nucleoside Analog: A Retrospective Observational Cohort Study of Treatment-Experienced Patients
por: Rolle, Charlotte-Paige M, et al.
Publicado: (2019)

Dolutegravir Monotherapy as Maintenance Strategy: A Meta-Analysis of Individual Participant Data From Randomized Controlled Trials
por: Fournier, Anna L, et al.
Publicado: (2022)

Stable HIV‐1 reservoirs on dolutegravir maintenance monotherapy: the MONODO study
por: Sculier, D, et al.
Publicado: (2018)

Total HIV DNA: a global marker of HIV persistence
por: Rouzioux, Christine, et al.
Publicado: (2018)

1766. Sustained Viral Suppression with Dolutegravir and Boosted Darunavir Dual Therapy Among Highly Treatment-Experienced Individuals
por: Hawkins, Kellie, et al.
Publicado: (2018)

Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Experienced (TE) Patients in France
por: Pialoux, Gilles, et al.
Publicado: (2015)

Emergent dolutegravir resistance in integrase-naïve, treatment experienced patients from Zimbabwe
por: Mandikiyana Chirimuta, Linda A., et al.
Publicado: (2022)

Predictors of virological failure in HIV‐1‐infected patients switching to dolutegravir maintenance monotherapy
por: Wijting, IEA, et al.
Publicado: (2018)

Pro-viral DNA and antiretroviral treatment simplification
por: Zucman, D, et al.
Publicado: (2010)

A Finger-Stick Whole-Blood HIV Self-Test as an HIV Screening Tool Adapted to the General Public
por: Prazuck, Thierry, et al.
Publicado: (2016)

Forgiveness of Dolutegravir-Based Triple Therapy Compared With Older Antiretroviral Regimens: A Prospective Multicenter Cohort of Adherence Patterns and HIV-RNA Replication
por: Parienti, Jean-Jacques, et al.
Publicado: (2021)

Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Naive and Treatment-Experienced Patients in Canada
por: Despiégel, Nicolas, et al.
Publicado: (2015)

Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIV
por: Guaraldi, Giovanni, et al.
Publicado: (2021)

Serum and cervicovaginal IgG immune responses against α7 and α9 HPV in non-vaccinated women at risk for cervical cancer: Implication for catch-up prophylactic HPV vaccination
por: Mboumba Bouassa, Ralph-Sydney, et al.
Publicado: (2020)

High viral suppression and detection of dolutegravir-resistance associated mutations in treatment-experienced Tanzanian adults living with HIV-1 in Dar es Salaam
por: Bwire, George M., et al.
Publicado: (2023)

It is possible to maintain a high compliance even in the long term: results from the Thermobrace study
por: Donzelli, S, et al.
Publicado: (2013)

Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort
por: Capetti, Amedeo F., et al.
Publicado: (2016)

Safety and Efficacy of Dolutegravir Plus Rilpivirine in Treatment-Experienced HIV-Infected Patients: The DORIVIR Study
por: Palacios, Rosario, et al.
Publicado: (2018)

Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study
por: Sáez-Cirión, Asier, et al.
Publicado: (2013)

In-Depth Characterization of Full-Length Archived Viral Genomes after Nine Years of Posttreatment HIV Control
por: Trémeaux, Pauline, et al.
Publicado: (2023)

Use of dolutegravir in two INI-experienced patients with multiclass resistance resulted in excellent virological and immunological responses
por: Marije Hofstra, Laura, et al.
Publicado: (2014)

Safety and efficacy of elvitegravir, dolutegravir, and raltegravir in a real-world cohort of treatment-naïve and -experienced patients
por: Brehm, Thomas Theo, et al.
Publicado: (2019)

Lopinavir to atazanavir or darunavir switch in HIV-1-infected patients with dyslipidemia: an observational study
por: Le Moal, G, et al.
Publicado: (2010)

Gel stored at low temperature maintains high viscosity even when injected via the water jet channel
por: Hiraki, Yuji, et al.
Publicado: (2022)

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study
por: Castagna, Antonella, et al.
Publicado: (2014)

Maintenance darunavir/ritonavir monotherapy to prevent perinatal HIV transmission, ANRS-MIE 168 MONOGEST study
por: Mandelbrot, Laurent, et al.
Publicado: (2023)

Impact de la prévalence du COVID-19 des personnels d’établissements médicosociaux sur le risque d’infection des résidents : étude prospective dans 17 EHPAD et MAS
por: Sève, A., et al.
Publicado: (2020)

Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients
por: Olearo, Flaminia, et al.
Publicado: (2019)

1262. Dolutegravir Plus 3TC In Antiretroviral Experienced Adults: Immunovirological Outcomes In a Multicenter Retrospective Cohort In Spain
por: Buzón-Martín, Luis, et al.
Publicado: (2022)

High Proportions of Patients With Advanced HIV Are Antiretroviral Therapy Experienced: Hospitalization Outcomes From 2 Sub-Saharan African Sites
por: Ousley, Janet, et al.
Publicado: (2018)

Maternal-Fetal Implications of SARS CoV-2 Infection during Pregnancy, Viral, Serological Analyses of Placenta and Cord Blood
por: Alouini, Souhail, et al.
Publicado: (2022)

The promise of paediatric dolutegravir
por: Golin, Rachel, et al.
Publicado: (2021)

Effect of Tenofovir Disoproxil Fumarate and Emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: A pilot, randomized, open-label phase 2 trial
por: Parienti, Jean-Jacques, et al.
Publicado: (2021)

Immune checkpoint blockade can synergize with radiation therapy, even in tumors resistant to checkpoint monotherapy
por: Dörrie, Jan
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_v9gc7gm9f0a1gfnrc60hb5rn2m